PKN3 and neoplasm: Atu027 is the delivery vehicle used, containing siRNAs against PKN3, which is the downstream effector of the phosphoinositide-3-kinase signaling pathway PKN3, in order to decrease tumor development and lymph node metastases to solid tumors and is now being explored in a clinical trial [13].